163 related articles for article (PubMed ID: 27188575)
21. A phase II study of axitinib in advanced neuroendocrine tumors.
Strosberg JR; Cives M; Hwang J; Weber T; Nickerson M; Atreya CE; Venook A; Kelley RK; Valone T; Morse B; Coppola D; Bergsland EK
Endocr Relat Cancer; 2016 May; 23(5):411-8. PubMed ID: 27080472
[TBL] [Abstract][Full Text] [Related]
22. [Axitinib in metastatic renal carcinomas: update of knowledge about side effects].
Albiges L; Izzedine H; Ederhy S; Robert C; Gravis G; Boyle H; Scotté F; Hartl D; Escudier B
Bull Cancer; 2014 Oct; 101(10):976-88. PubMed ID: 25373697
[TBL] [Abstract][Full Text] [Related]
23. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
24. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
Takahashi H; Ojima H; Shimizu H; Furuse J; Furukawa H; Shibata T
Jpn J Clin Oncol; 2014 Jun; 44(6):570-8. PubMed ID: 24755544
[TBL] [Abstract][Full Text] [Related]
25. Individualized dosing with axitinib: rationale and practical guidance.
Schmidinger M; Danesi R; Jones R; McDermott R; Pyle L; Rini B; Négrier S
Future Oncol; 2018 Apr; 14(9):861-875. PubMed ID: 29264944
[TBL] [Abstract][Full Text] [Related]
26. Axitinib for the treatment of metastatic renal cell carcinoma: recommendations for therapy management to optimize outcomes.
Larkin J; Fishman M; Wood L; Negrier S; Olivier K; Pyle L; Gorbunova V; Jonasch E; Andrews L; Staehler M
Am J Clin Oncol; 2014 Aug; 37(4):397-403. PubMed ID: 23357974
[TBL] [Abstract][Full Text] [Related]
27. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.
McNamara MG; Le LW; Horgan AM; Aspinall A; Burak KW; Dhani N; Chen E; Sinaei M; Lo G; Kim TK; Rogalla P; Bathe OF; Knox JJ
Cancer; 2015 May; 121(10):1620-7. PubMed ID: 25565269
[TBL] [Abstract][Full Text] [Related]
28. Axitinib-induced acute pancreatitis: a case report.
Péron J; Khenifer S; Potier V; Vitry T; Pasquet F; Rassat R; Pavic M
Anticancer Drugs; 2014 Apr; 25(4):478-9. PubMed ID: 24398664
[TBL] [Abstract][Full Text] [Related]
29. Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Wirtz ED; Hoshino D; Maldonado AT; Tyson DR; Weaver AM
JAMA Otolaryngol Head Neck Surg; 2015 Jun; 141(6):543-9. PubMed ID: 25855885
[TBL] [Abstract][Full Text] [Related]
30. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma.
Fruehauf J; Lutzky J; McDermott D; Brown CK; Meric JB; Rosbrook B; Shalinsky DR; Liau KF; Niethammer AG; Kim S; Rixe O
Clin Cancer Res; 2011 Dec; 17(23):7462-9. PubMed ID: 21976544
[TBL] [Abstract][Full Text] [Related]
31. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
[TBL] [Abstract][Full Text] [Related]
32. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?
Goldstein R; Pickering L; Larkin J
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625
[TBL] [Abstract][Full Text] [Related]
33. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.
Lu L; Saha D; Martuza RL; Rabkin SD; Wakimoto H
J Neurooncol; 2015 Jan; 121(1):91-100. PubMed ID: 25213669
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.
Carmichael C; Lau C; Josephson DY; Pal SK
Clin Adv Hematol Oncol; 2012 May; 10(5):307-14. PubMed ID: 22706540
[TBL] [Abstract][Full Text] [Related]
35. Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Cai Y; Dodhia S; Su GH
Oncotarget; 2017 Mar; 8(13):22203-22217. PubMed ID: 28108737
[TBL] [Abstract][Full Text] [Related]
36. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
[TBL] [Abstract][Full Text] [Related]
37. Axitinib: a review in advanced renal cell carcinoma.
Keating GM
Drugs; 2015 Nov; 75(16):1903-13. PubMed ID: 26487541
[TBL] [Abstract][Full Text] [Related]
38. Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models.
Giddabasappa A; Lalwani K; Norberg R; Gukasyan HJ; Paterson D; Schachar RA; Rittenhouse K; Klamerus K; Mosyak L; Eswaraka J
Exp Eye Res; 2016 Apr; 145():373-379. PubMed ID: 26927930
[TBL] [Abstract][Full Text] [Related]
39. Breakthrough targeted therapeutic approaches to squamous cell carcinoma of the head and neck.
Mangano A; Mangano A; Lianos GD; Roukos DH; Caprioglio A; Dionigi G
Future Oncol; 2015; 11(1):9-12. PubMed ID: 25572780
[No Abstract] [Full Text] [Related]
40. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]